Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Feb 2020
Randomized Controlled TrialLong-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
Randomized controlled trials have shown the efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis. ⋯ Brodalumab is well tolerated and showed robust efficacy for more than 2 years.
-
J. Am. Acad. Dermatol. · Feb 2020
Randomized Controlled TrialRuxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study.
There are currently no treatments for alopecia areata (AA) that are universally effective or approved by the US Food and Drug Administration. Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemic adverse effects. ⋯ The 1.5% ruxolitinib cream did not have a significant effect in patients with AA.
-
J. Am. Acad. Dermatol. · Feb 2020
Multicenter StudyDupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Significant unmet need exists for long-term treatment of moderate to severe atopic dermatitis (AD). ⋯ The safety and efficacy profile from this study supports the role of dupilumab as continuous long-term treatment for patients with moderate to severe AD.